{"denoms":[{"counts":[{"groupId":"BG000","value":"77"},{"groupId":"BG001","value":"75"},{"groupId":"BG002","value":"152"}],"units":"Participants"}],"groups":[{"description":"Elotuzumab: Solution; Intravenous (IV); 10 mg/kg; (Cycles 1 \\& 2: Days 1, 8 \\& 15; Cycles 3-8: Days 1 \\& 11; Cycle 9+: Days 1 \\& 15); Until participant meets criteria for discontinuation of drug Bortezomib: Solution; IV; 1.3 mg/m\\^2; (Cycles 1 - 8: Days 1, 4, 8, 11; Cycles 9+: Days 1, 8, 15); Until criteria met for discontinuation of drug. Days of Elotuzumab infusion: Dexamethasone (8mg IV + 8mg Oral) administered. Other days Dexamethasone 20 mg Oral administered Dexamethasone: Tablets; 20 mg; (Cycles 1\\& 2: once daily on Days 2, 4, 5, 8, 9, 11; Cycles 3-8: once daily on Days 2, 4, 5, 9, 12; Cycles 9+: once daily on Days 2, 8, 9, 16); Until criteria met for discontinuation. Dexamethasone: Tablets; 8 mg; (Cycles 1\\& 2: Days 1, 8, 15; Cycles 3-8: Days 1 \\&11; Cycles 9+; Days 1 \\& 15); Until criteria met for discontinuation of drug. Dexamethasone: Solution; IV; 8 mg; (Cycles 1\\& 2: Days 1, 8, 15; Cycles 3-8: Days 1 \\&11; Cycles 9+; Days 1 \\& 15); Until criteria met for discontinuation","id":"BG000","title":"Elotuzumab + Bortezomib + Dexamethasone"},{"description":"Bortezomib: Solution; IV; 1.3 mg/m\\^2; (Cycles 1 - 8: Days 1, 4, 8, 11; Cycles 9+: Days 1, 8, 15); Until criteria met for discontinuation of study drug. Dexamethasone: Tablets; 20 mg; (Cycles 1-8 once daily on Days 1, 2, 4, 5, 8, 9, 11, 12; Cycles 9+ once daily on Days 1, 2, 8, 9, 15, 16); Until criteria is met for discontinuation of study drug","id":"BG001","title":"Bortezomib + Dexamethasone"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.48","value":"65.4"},{"groupId":"BG001","spread":"10.34","value":"65.1"},{"groupId":"BG002","spread":"9.88","value":"65.3"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"34"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"67"}]}],"title":"< 65 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"56"}]}],"title":"≥65 and <75 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"29"}]}],"title":">= 75 years"}],"description":"Less than (\\<); Greater than, equal to (≥).","paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"38"},{"groupId":"BG002","value":"73"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"42"},{"groupId":"BG001","value":"37"},{"groupId":"BG002","value":"79"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"48"}]}],"title":"United States"},{"categories":[{"measurements":[{"groupId":"BG000","value":"34"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"66"}]}],"title":"Italy"},{"categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"21"}]}],"title":"France"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"17"}]}],"title":"Spain"}],"description":"Number of participants enrolled, by country, were summarized.","paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"38"},{"groupId":"BG001","value":"37"},{"groupId":"BG002","value":"75"}]}],"title":"Yes"},{"categories":[{"measurements":[{"groupId":"BG000","value":"39"},{"groupId":"BG001","value":"38"},{"groupId":"BG002","value":"77"}]}],"title":"No"}],"description":"Categories presented as they were at randomization based on information collected via the Interactive Voice Recognition System (IVRS) system.","paramType":"COUNT_OF_PARTICIPANTS","title":"Prior Protease Inhibitor Use","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"55"},{"groupId":"BG001","value":"54"},{"groupId":"BG002","value":"109"}]}],"title":"Yes"},{"categories":[{"measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"43"}]}],"title":"No"}],"description":"An allele is any one of a series of 2 or more different genes that may be on a specific chromosome. Categories presented as they were at randomization based on information collected via the Interactive Voice Recognition System (IVRS) system.","paramType":"COUNT_OF_PARTICIPANTS","title":"Presence of At Least 1 FcγRIIIa V allele","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"55"},{"groupId":"BG001","value":"51"},{"groupId":"BG002","value":"106"}]}],"title":"1 line of prior therapy"},{"categories":[{"measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"46"}]}],"title":"2 or 3 lines of prior therapy"}],"description":"Categories presented as they were at randomization based on information collected via the Interactive Voice Recognition System (IVRS) system.","paramType":"COUNT_OF_PARTICIPANTS","title":"Number of Prior Lines of Therapy","unitOfMeasure":"Participants"}],"populationDescription":"All enrolled participants who were randomized to a treatment arm were summarized."}